We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Intravenous Gene Therapy Protects Tissue During Whole-Body Radiation

By Biotechdaily staff writers
Posted on 30 Nov 2006
Gene therapy administered intravenously could be used as an agent to protect vital organs and tissues from the effects of ionizing radiation in the event of large-scale exposure from a radiologic or nuclear dirty bomb, according to a recent laboratory study with mice. More...


"Ionizing radiation can be extremely damaging to cells, tissues, organs and organ systems,” noted Joel S. Greenberger, M.D., professor and chairman, department of radiation oncology at the University of Pittsburgh School of Medicine (PA, USA). "In previous studies, we demonstrated that gene therapy can be both swallowed in pill form and inhaled through a nebulizer prior to radiation exposure to protect healthy tissues from damage. In this study, we found that the same therapy administered intravenously also offers protection during exposure to whole-body irradiation.” Dr. Greenberger added that intravenous administration could potentially offer wide-reaching protection to the public in the event of a terrorist attack since experts believe a significant number of the population would die within 30 days of receiving a large dose of radiation to the entire body.

The researchers presented their study's findings in November 2006 at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Philadelphia (PA, USA).

In the study, mice were used to evaluate the protective effects of manganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapy on the bone marrow during whole-body irradiation. The researchers found that in a control group of mice that received an initial 9 Gy dose of radiation there was 80% survival at 30 days compared to 93.3% survival during the same length of time for an experimental group of mice that were injected with MnSOD-PL prior to irradiation. As the level of radiation exposure was increased, survival rates in the mice injected with MnSOD-PL before exposure increased considerably. For example, at 9.5 Gy, mice in the control group had a survival rate of 53%, whereas mice in the experimental group had a survival rate of 87%. Following irradiation to 9.75 Gy, only 12.5% of the mice in the control group survived, while 75% of the MnSOD-PL group survived.

"Intravenous administration of gene therapy appears to prevent the damaging effects of radiation, suggesting it is a viable delivery method,” said Dr. Greenberger. "Future clinical studies will tell us whether this therapy can protect people from the deadly effects of radiation.”



Related Links:
University of Pittsburgh School of Medicine

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Multi-Chamber Washer-Disinfector
WD 390
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.